For a better experience of our website please update you web browser from IE11 to Microsoft Edge or an alternative modern browser such as Google Chrome. Thank you.
Your partner in science for end-to-end CRDMO solutions
Jubilant Biosys Limited (“Biosys”), a wholly owned subsidiary of Jubilant Life Sciences Limited, today announced completion of the merger with its sister company Jubilant Chemsys Limited, based in Noida, India. The combined entities will now operate as Jubilant Biosys Limited.
The merger will simplify operations and provide customers with a single brand access for a wide range of discovery, IND and PR&D and GMP development services. Biosys had earlier announced significant investment in building new state-of-the-art research facilities in Greater Noida and in Bengaluru, India to cater to increasing customer demand for its functional services (medicinal & synthetic chemistry, structural biology, DMPK, Biology & GMP scale-up) and notably integrated drug discovery services.
“We are delighted to make this merger happen and focus our investments for growth to expand both the chemistry as well as integrated drug discovery capabilities. It provides clarity to customers and enables us to better deliver on our “4D” promise of accelerating the discovery process through increased digitization of our operations and information flow.”
Marcel Velterop
President – Drug Discovery Services & CDMO – Jubilant Biosys Limited
Jubilant Biosys, a Bengaluru based wholly owned subsidiary of Jubilant Life Sciences Ltd, offers contract research & development services for global pharmaceutical innovators. Biosys has demonstrated expertise in functional services such as Biology, DMPK, Toxicology as well as Medicinal Chemistry, PR&D and GMP scale-up capabilities up to phase II. It has a proven track record of delivering over 75 integrated programs in multiple therapeutic areas including but not limited to Oncology, Metabolic Disorders, Pain & Inflammation, CNS and expanding into Rare Diseases. Its sister company, TrialStat Solution Inc., provides an advanced EDC platform to accelerate clinical trials’ data capture and processing.
Jubilant Life Sciences Limited is an integrated global pharmaceutical and life sciences company engaged in Pharmaceuticals, Life Science Ingredients and Drug Discovery & Development Solutions businesses. Pharmaceuticals business, through Jubilant Pharma Limited, Singapore (JPL), is engaged in manufacturing and supply of Radiopharmaceuticals with a network of over 50 radio-pharmacies in the US, Allergy Therapy Products, Contract Manufacturing of Sterile Injectables & Non-sterile products, APIs and Solid Dosage Formulations through six USFDA approved manufacturing facilities in the US, Canada and India. The Life Science Ingredients segment is engaged in Specialty Intermediates, Nutritional Products and Life Science Chemicals through five manufacturing facilities in India. Drug Discovery & Development Solutions comprises Drug Discovery Services (DDS) business through Jubilant Biosys Limited and Proprietary Drug Discovery business through Jubilant Therapeutics Inc. DDS provides innovative and collaborative research through two world class research centers in Bangalore and Noida in India and Jubilant Therapeutics Inc is an innovative biopharmaceutical company developing breakthrough therapies in the area of oncology and auto-immune disorders. Jubilant Life Sciences Limited has a team of around 8,000 multicultural people across the globe and is committed to deliver value to its customers across over 100 countries. The Company is well recognized as a ‘Partner of Choice’ by leading pharmaceuticals and life sciences companies globally.
For more info: www.jubl.com.
For more information, please contact:
Drishti Asthana
Jubilant Biosys Limited
Ph: +91- 9899033635
E-mail: drishti.asthana@jubilantbiosys.com